Immunization with Hexon Modified Adenoviral Vectors Integrated with gp83 Epitope Provides Protection against Trypanosoma cruzi Infection

PLoS Neglected Tropical Diseases

Volumn 8, Issue 8, 2014, Pages

  Farrow, Anitra L ^a   Rachakonda, Girish ^b   Gu, Linlin ^a   Krendelchtchikova, Valentina ^a   Nde, Pius N ^b   Pratap, Siddharth ^b   Lima, Maria F ^b   Villalta, Fernando ^b   Matthews, Qiana L ^a,c  

^a University of Alabama at Birmingham   (United States)

^b MEHARRY MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CAPSID PROTEIN; EPITOPE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PROTOZOAL VACCINE; PROTOZOON ANTIBODY; RECOMBINANT VACCINE; HEXON CAPSID PROTEIN, ADENOVIRUS; PROTOZOAL PROTEIN; VARIANT SURFACE GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY COMBINING SITE; ARTICLE; CELLULAR IMMUNITY; CHAGAS DISEASE; CONTROLLED STUDY; DISEASE CARRIER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE MICROSCOPY; GENETIC RECOMBINATION; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; HUMORAL IMMUNITY; ID50 (INFECTIOUS); MOUSE; NONHUMAN; PARASITEMIA; POLYMERASE CHAIN REACTION; SURVIVAL RATE; TRYPANOSOMA CRUZI; VACCINATION; VIRION; VIRUS NEUTRALIZATION; WESTERN BLOTTING; ADENOVIRIDAE; ANIMAL; C57BL MOUSE; GENE VECTOR; GENETICS; HEK293 CELL LINE; IMMUNOLOGY;

ADENOVIRIDAE; ANIMALS; CAPSID PROTEINS; CHAGAS DISEASE; FEMALE; GENETIC VECTORS; HEK293 CELLS; HUMANS; MICE; MICE, INBRED C57BL; PROTOZOAN PROTEINS; TRYPANOSOMA CRUZI; VARIANT SURFACE GLYCOPROTEINS, TRYPANOSOMA;

EID: 84941252984     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003089     Document Type: Article

References (70)

1. Chagas C, (1988) A short chronicle of the discovery of Chagas' disease. Pacing Clin Electrophysiol 11: 1108–1113.
2. World Health Organization (2013) Chagas disease (American trypanosomiasis).
3. Gascon J, Bern C, Pinazo MJ, (2010) Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop 115: 22–27.
4. Schmunis GA, Yadon ZE, (2010) Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop 115: 14–21.
5. Bern C, Kjos S, Yabsley MJ, Montgomery SP, (2011) Trypanosoma cruzi and Chagas' Disease in the United States. Clin Microbiol Rev 24: 655–681.
6. Rassi A, JrRassi A, Marin-Neto JA, (2010) Chagas disease. Lancet 375: 1388–1402.
7. Castro JA, Diaz de Toranzo EG, (1988) Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease). Biomed Environ Sci 1: 19–33.
8. Urbina JA, (2010) Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 115: 55–68.
9. Guedes PM, Silva GK, Gutierrez FR, Silva JS, (2011) Current status of Chagas disease chemotherapy. Expert Rev Anti Infect Ther 9: 609–620.
10. Ono T, Yamaguchi Y, Oguma T, Takayama E, Takashima Y, et al. (2012) Actively induced antigen-specific CD8+ T cells by epitope-bearing parasite pre-infection but not prime/boost virus vector vaccination could ameliorate the course of Plasmodium yoelii blood-stage infection. Vaccine 30: 6270–6278.
11. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, et al. (2003) Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77: 6305–6313.
12. Liang X, Casimiro DR, Schleif WA, Wang F, Davies ME, et al. (2005) Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. J Virol 79: 12321–12331.
13. Shiver JW, Emini EA, (2004) Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 55: 355–372.
14. Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, et al. (2004) Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci U S A 101 Suppl 2: 14567–14571.
15. Matthews QL, Sibley DA, Wu H, Li J, Stoff-Khalili MA, et al. (2006) Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion. Mol Imaging 5: 510–519.
16. Matthews QL, Fatima A, Tang Y, Perry BA, Tsuruta Y, et al. (2010) HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS One 5: e11815.
17. Tang Y, Wu H, Ugai H, Matthews QL, Curiel DT, (2009) Derivation of a triple mosaic adenovirus for cancer gene therapy. PLoS One 4: e8526.
18. Vorburger S, Hunt KK, (2001) Adenoviral Gene Therapy. The Oncologist 7: 46–59.
19. Matthews QL, Yang P, Wu Q, Belousova N, Rivera AA, et al. (2008) Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol J 5: 98.
20. Shiratsuchi T, Rai U, Krause A, Worgall S, Tsuji M, (2010) Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J Clin Invest 120: 3688–3701.
21. McConnell MJ, Danthinne X, Imperiale MJ, (2006) Characterization of a permissive epitope insertion site in adenovirus hexon. J Virol 80: 5361–5370.
22. Worgall S, Krause A, Rivara M, Hee KK, Vintayen EV, et al. (2005) Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J Clin Invest 115: 1281–1289.
23. Villalta F, Smith CM, Ruiz-Ruano A, Lima MF, (2001) A ligand that Trypanosoma cruzi uses to bind to mammalian cells to initiate infection. FEBS Lett 505: 383–388.
24. Villalta F, Lima MF, Ruiz-Ruano A, Zhou L, (1992) Attachment of Trypanosoma cruzi to host cells: a monoclonal antibody recognizes a trypomastigote stage-specific epitope on the gp 83 required for parasite attachment. Biochem Biophys Res Commun 182: 6–13.
25. Lima MF, Villalta F, (1989) Trypanosoma cruzi trypomastigote clones differentially express a parasite cell adhesion molecule. Mol Biochem Parasitol 33: 159–170.
26. Villalta F, Dobish MC, Nde PN, Kleshchenko YY, Hargrove TY, et al. (2013) VNI cures acute and chronic experimental Chagas disease. J Infect Dis 208: 504–511.
27. Lepesheva GI, Hargrove TY, Anderson S, Kleshchenko Y, Furtak V, et al. (2010) Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi. J Biol Chem 285: 25582–25590.
28. Wu H, Han T, Belousova N, Krasnykh V, Kashentseva E, et al. (2005) Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol 79: 3382–3390.
29. Wu H, Dmitriev I, Kashentseva E, Seki T, Wang M, et al. (2002) Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol 76: 12775–12782.
30. Gu L, Li ZC, Krendelchtchikov A, Krendelchtchikova V, Wu H, et al. (2013) Using multivalent adenoviral vectors for HIV vaccination. PLoS One 8: e60347.
31. Villalta F, Kierszenbaum F, (1983) Immunization against a challenge with insect vector, metacyclic forms of Trypanosoma cruzi simulating a natural infection. Am J Trop Med Hyg 32: 273–276.
32. Johnson CA, Rachakonda G, Kleshchenko YY, Nde PN, Madison MN, et al. (2013) Cellular response to Trypanosoma cruzi infection induces secretion of defensin alpha-1, which damages the flagellum, neutralizes trypanosome motility, and inhibits infection. Infect Immun 81: 4139–4148.
33. Johnson CA, Kleshchenko YY, Ikejiani AO, Udoko AN, Cardenas TC, et al. (2012) Thrombospondin-1 interacts with Trypanosoma cruzi surface calreticulin to enhance cellular infection. PLoS One 7: e40614.
34. Villalta F, Madison MN, Kleshchenko YY, Nde PN, Lima MF, (2008) Molecular analysis of early host cell infection by Trypanosoma cruzi. Front Biosci 13: 3714–3734.
35. Agusti R, Couto AS, Campetella OE, Frasch AC, de Lederkremer RM, (1997) The trans-sialidase of Trypanosoma cruzi is anchored by two different lipids. Glycobiology 7: 731–735.
36. Villalta F, Lima MF, Howard SA, Zhou L, Ruiz-Ruano A, (1992) Purification of a Trypanosoma cruzi trypomastigote 60-kilodalton surface glycoprotein that primes and activates murine lymphocytes. Infect Immun 60: 3025–3032.
37. Villalta F, Zhang Y, Bibb KE, Burns JM, JrLima MF, (1998) Signal transduction in human macrophages by gp83 ligand of Trypanosoma cruzi: trypomastigote gp83 ligand up-regulates trypanosome entry through the MAP kinase pathway. Biochem Biophys Res Commun 249: 247–252.
38. Nde PN, Simmons KJ, Kleshchenko YY, Pratap S, Lima MF, et al. (2006) Silencing of the laminin gamma-1 gene blocks Trypanosoma cruzi infection. Infect Immun 74: 1643–1648.
39. Bryan MA, Guyach SE, Norris KA, (2010) Specific humoral immunity versus polyclonal B cell activation in Trypanosoma cruzi infection of susceptible and resistant mice. PLoS Negl Trop Dis 4: e733.
40. Rowland EC, Mikhail KS, McCormick TS, (1992) Isotype determination of anti-Trypanosoma cruzi antibody in murine Chagas' disease. J Parasitol 78: 557–561.
41. el Bouhdidi A, Truyens C, Rivera MT, Bazin H, Carlier Y, (1994) Trypanosoma cruzi infection in mice induces a polyisotypic hypergammaglobulinaemia and parasite-specific response involving high IgG2a concentrations and highly avid IgG1 antibodies. Parasite Immunol 16: 69–76.
42. d'Imperio Lima MR, Eisen H, Minoprio P, Joskowicz M, Coutinho A, (1986) Persistence of polyclonal B cell activation with undetectable parasitemia in late stages of experimental Chagas' disease. J Immunol 137: 353–356.
43. Padilla AM, Bustamante JM, Tarleton RL, (2009) CD8+ T cells in Trypanosoma cruzi infection. Curr Opin Immunol 21: 385–390.
44. Hoft DF, Eickhoff CS, (2005) Type 1 immunity provides both optimal mucosal and systemic protection against a mucosally invasive, intracellular pathogen. Infect Immun 73: 4934–4940.
45. Tarleton RL, (2007) Immune system recognition of Trypanosoma cruzi. Curr Opin Immunol 19: 430–434.
46. Martin D, Tarleton R, (2004) Generation, specificity, and function of CD8+ T cells in Trypanosoma cruzi infection. Immunol Rev 201: 304–317.
47. Wizel B, Nunes M, Tarleton RL, (1997) Identification of Trypanosoma cruzi trans-sialidase family members as targets of protective CD8+ TC1 responses. J Immunol 159: 6120–6130.
48. Costa F, Franchin G, Pereira-Chioccola VL, Ribeirao M, Schenkman S, et al. (1998) Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice. Vaccine 16: 768–774.
49. Fujimura AE, Kinoshita SS, Pereira-Chioccola VL, Rodrigues MM, (2001) DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene. Infect Immun 69: 5477–5486.
50. Katae M, Miyahira Y, Takeda K, Matsuda H, Yagita H, et al. (2002) Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy. Infect Immun 70: 4833–4840.
51. Chou B, Hisaeda H, Shen J, Duan X, Imai T, et al. (2008) Critical contribution of immunoproteasomes in the induction of protective immunity against Trypanosoma cruzi in mice vaccinated with a plasmid encoding a CTL epitope fused to green fluorescence protein. Microbes Infect 10: 241–250.
52. Serna C, Lara JA, Rodrigues SP, Marques AF, Almeida IC, et al. (2014) A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease. Vaccine 32: 3525–3532.
53. Vasconcelos JR, Boscardin SB, Hiyane MI, Kinoshita SS, Fujimura AE, et al. (2003) A DNA-priming protein-boosting regimen significantly improves type 1 immune response but not protective immunity to Trypanosoma cruzi infection in a highly susceptible mouse strain. Immunol Cell Biol 81: 121–129.
54. Vasconcelos JR, Bruna-Romero O, Araujo AF, Dominguez MR, Ersching J, et al. (2012) Pathogen-induced proapoptotic phenotype and high CD95 (Fas) expression accompany a suboptimal CD8+ T-cell response: reversal by adenoviral vaccine. PLoS Pathog 8: e1002699.
55. Buckner FS, Wipke BT, Van Voorhis WC, (1997) Trypanosoma cruzi infection does not impair major histocompatibility complex class I presentation of antigen to cytotoxic T lymphocytes. Eur J Immunol 27: 2541–2548.
56. Wrightsman RA, Manning JE, (2000) Paraflagellar rod proteins administered with alum and IL-12 or recombinant adenovirus expressing IL-12 generates antigen-specific responses and protective immunity in mice against Trypanosoma cruzi. Vaccine 18: 1419–1427.
57. Machado AV, Cardoso JE, Claser C, Rodrigues MM, Gazzinelli RT, et al. (2006) Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase. Hum Gene Ther 17: 898–908.
58. Miyahira Y, Takashima Y, Kobayashi S, Matsumoto Y, Takeuchi T, et al. (2005) Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection. Infect Immun 73: 7356–7365.
59. Barbosa RP, Filho BG, Dos Santos LI, Junior PA, Marques PE, et al. (2013) Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection. PLoS One 8: e61795.
60. Nogueira RT, Nogueira AR, Pereira MC, Rodrigues MM, Galler R, et al. (2011) Biological and immunological characterization of recombinant Yellow Fever 17D viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genome. Virol J 8: 127.
61. Duan X, Yonemitsu Y, Chou B, Yoshida K, Tanaka S, et al. (2009) Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2. Vaccine 27: 6154–6159.
62. Thacker EE, Timares L, Matthews QL, (2009) Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccines 8: 761–777.
63. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, et al. (1999) Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6: 1574–1583.
64. Schagen FH, Ossevoort M, Toes RE, Hoeben RC, (2004) Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion. Crit Rev Oncol Hematol 50: 51–70.
65. Zaiss AK, Machado HB, Herschman HR, (2009) The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem 108: 778–790.
66. Tian X, Su X, Li H, Li X, Zhou Z, et al. (2011) Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon. Virus Res 160: 214–220.
67. Soloff AC, Liu X, Gao W, Day RD, Gambotto A, et al. (2009) Adenovirus 5- and 35-based immunotherapy enhances the strength but not breadth or quality of immunity during chronic SIV infection. Eur J Immunol 39: 2437–2449.
68. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, et al. (2007) Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 81: 4654–4663.
69. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ, (1990) Basic local alignment search tool. J Mol Biol 215: 403–410.
70. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25: 3389–3402.